News

  1. Top page
  2. News
  3. We have invested in Nexuspiral Corporation, a company that uses cutting-edge genome design technology to overcome as many diseases as possible, including rare diseases.
2021/09/01
  • News
  • Investment Company
  • Supported Companies

We have invested in Nexuspiral Corporation, a company that uses cutting-edge genome design technology to overcome as many diseases as possible, including rare diseases.

 

(Head office: Sumida-ku, Tokyo; President: Yoshinobu Osaka) has invested in Nexuspiral Corporation (Head office: Kobe City, Hyogo Prefecture; Representative Director: Naoyuki Masuda).

The company aims to save as many patients as possible by taking on the challenge of treating various intractable diseases such as hereditary rare diseases. The ST method (Sense-strand Technology), invented by Dr. Hideaki Maseda of the University of Tokushima (currently National Institute of Advanced Industrial Science and Technology), makes it possible to edit genomes without using foreign proteins. For pharmaceutical applications, direct editing of targeted genes by the ST method is expected to enable in vivo editing without the use of viral vectors or foreign proteins.

Contact]
Company Name Nexuspiral Corporation
Representative Naoyuki Masuda, Representative Director
Location: Entrepreneurship Plaza Hyogo, 56 Naniwa-cho, Chuo-ku, Kobe, Hyogo 650-0035, Japan
    Kobe Research Institute, 6-3-7 Minatojima Minami-cho, Chuo-ku, Kobe-shi, Hyogo, Japan Creative Lab Kobe Startup Creative Lab.
URL http://nexuspiral.co.jp
Contact [email protected]

Company name GLOKA LINK Inc.
Representative Yoshinobu Osaka, Representative Director
Location Center of Garage, 1-16-3 Yokogawa, Sumida-ku, Tokyo 130-0003, Japan
URL https://glocalink.com
Contact https://glocalink.com/contact/